Realbotix Reports Financial Results for Fiscal Year Ended September 30, 2025
Executive Summary
- Realbotix reported FY 2025 revenue of $2.0 M (↑121%) and narrowed its net loss to $6.3 M despite higher operating expenses.
- Completed a brokered private placement of 14 M units at CAD $0.50 each, raising CAD $7.0 M; the company is now debt‑free with >12 months of cash runway.
- Announced a reverse take‑over transaction with NASDAQ‑listed Onconetix that will give Realbotix 75‑90% ownership of the combined entity and support commercial scale‑up.
Key Details
- Financial Highlights FY 2025
- Revenue: $2.0 M (↑121% YoY).
- Gross margin: 34.3% (up from 19.8%).
- Operating expenses: $6.9 M (incl. $1.4 M non‑cash share‑based compensation).
-
Net loss from continuing operations: $6.3 M (improved from $12.5 M).
-
Cryptocurrency Disposition
-
Fully liquidated crypto holdings in Aug 2025, converting to fiat and generating cash proceeds of $9.4 M; $4.0 M recognized as gains.
-
Debt Position
-
All debt repaid post‑September 30 2025; company now debt‑free.
-
Private Placement (Oct 24 2025)
- Units sold: 14,000,000
- Price per unit: CAD $0.50
- Gross proceeds: CAD $7.0 M
-
Unit composition: 1 share + 1 warrant (CAD $0.75 strike, expires Oct 24 2030).
-
Cash Position (as of Mar 6 2026)
- Cash & receivable from Tokens.com domain sale: approx. $8.6 M USD (CAD $11.8 M).
- Monthly cash burn: ~$425k (excludes unforeseen expenses).
-
Runway: >12 months at current spend.
-
Strategic Partnerships & Commercial Wins
- Exclusive partnership with Grupo Kuo (Sept 10 2025) to bring robots to Spain & Portugal.
-
Enterprise clients secured: Ericsson and The FUTR Corporation for AI agents & humanoid robots.
-
Product & Marketing Milestones
- Launched AI chatbot “Ask Aria” (Sept 4 2025).
-
Demonstrated flagship robot Aria at Times Square, NYC (Sept 25 2025) and other high‑profile venues (CNN, CES, Las Vegas Fashion Show Mall).
-
Leadership Appointments
- Scott Meyers, CPA – Chief Financial Officer (Jan 12 2026).
-
Eric Olsen – Head of Operations & Commercialization for humanoid robots (Feb 9 2026).
-
Reverse Take‑Over Transaction (Feb 11 2026)
- Target: Onconetix (NASDAQ listed).
- Structure: No new shares issued by Realbotix; upon closing, Realbotix will own 75‑90% of the combined entity.
-
No shareholder action required; no share consolidation.
-
Investor Call
- Date & Time: March 10 2026, 1:00 p.m. ET (Zoom webinar).
Notable Quotes
“2025 was a year of taking our exceptional tech and building a supporting business around it… Our anticipated transition to a NASDAQ‑listed vehicle will broaden our investor base and access to capital, while allowing us to retain significant upside.” – Andrew Kiguel, CEO, Realbotix.